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ABSTRACT 
Creating a Colonic Organoid Model for Studying Colorectal Cancer. (May 2014) 
 
Kendra Marie Kelly 
Department of Biochemistry and Biophysics 
Texas A&M University 
 
Research Advisor: Dr. Robert Chapkin 
Department of Nutrition and Food Science 
 
Although significant research is currently being conducted to study human cancers, the use of in 
vivo models is time consuming and costly. Recent findings have documented the use of mouse 
intestinal crypt organoids as a model system using Lgr5+ stem cells to express cancer related 
genes in a targeted manner. The objective of this research project is to successfully transform 
colonic mouse organoids with a mutant form of the K-ras oncogene. This is relevant because 
patients diagnosed with colon cancer often express a mutated copy of the K-ras gene within 
colonic tumors. Thus, the transduction of a mutant gene into colonic organoids will create an ex 
vivo model for studying colon cancer.  
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CHAPTER I 
INTRODUCTION 
 
Background 
Colorectal cancer remains a serious problem in the United States, affecting 6% of the population. 
Advances have been made in the study of the disease and preventative measures are currently 
being investigated. In order to study cancerous and premalignant tissue, transgenic mice are used 
as a model system. Some disadvantages involving the use of mice include the long generation 
time and the high cost of breeding and raising mouse colonies. More recent findings have 
demonstrated that intestinal cells can be grown as three-dimensional organoid systems ex vivo 
(1). Organoids have been developed from many different types of tissue including muscle, 
stomach, and intestinal cells with each organoid culture reproducing the architecture of the in 
vivo organ (1, 2). 
 
The viral transduction of genes is an established method to manipulate a genome both ex vivo 
and in vitro. This is noteworthy, because organoid models can be transformed through a 
retroviral transduction system (1). The use of organoid models will allow for a cost-effective 
evaluation of transformed animal genomes relevant to human disease. 
 
Ras genes 
The mammalian ras gene family—consisting of H-ras, N-ras, K4A-ras, and K4B-ras—functions 
in cell proliferation and determination (3). In addition, the K-ras gene has a unique and essential 
role in mouse embryogenesis (3). It has been documented that ras genes are mutated in over 30% 
3 
 
of human tumors and a mutation in the 12th codon of K-ras is found in ~40% of colonic tumors 
(3, 4). Mutated K-ras is known to occur more frequently in patients with colorectal cancer as the 
tumor progresses (5). Due to the frequent mutation rate associated with K-ras and its function, 
this gene has been selected as a prime target for cancer therapy (6). Targeting dysregulated K-ras 
has led to antitumor activity, however, ras driven tumors are often refractory to conventional 
therapies and clinically effective targeted therapy has not yet been developed (6).  
 
K-ras as a model for colorectal cancer 
A mutant human K-ras gene will be inserted into a retroviral plasmid for the purpose of 
transforming colonic organoids using a tamoxifen (4-OHT) inducible cre-recombinase  
Figure 1. Retroviral plasmid construct (1). 
 
mechanism. As illustrated in Figure 1, transformed organoids will initially fluoresce red under 
ultraviolet (UV) illumination. Addition of 4-OHT to the culture media will induce the 
cre-recombinase reaction to excise the DNA between the loxp sites. After dsRed is excised, 
eGFP will be expressed and the transformed cells will fluoresce green in UV light. The mutated 
K-ras gene will be ligated into the plasmid between the second loxp site and the eGFP. In this 
manner, the transformed organoids, after excision of dsRed, will express the mutant K-ras gene. 
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This ex vivo model can be utilized to study the metabolism of oncogenic colonocytes vs isogenic 
(control) colonocytes. 
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CHAPTER II 
METHODS 
 
Mice 
Lgr5+-GFP mice between the ages of nine and twelve weeks were used. The handling and care of 
the mice were in accordance to the Animal Use Protocol 2010-285. 
 
Colon crypt isolation 
Primary colonic crypts were released in 20 mM EDTA at 37°C during a 30 minute incubation. 
After incubation, the crypts were pelleted at 500g for 5 min and counted. The isolated crypts 
were resuspended in Matrigel (BD Biosciences) at 750 crypts per 50 µL, then plated in a 24-well 
plate. The crypts were fed with 500 µL of crypt culture medium (50% Wnt3a conditioned 
medium, 47% Advanced DMEM/F12 (Invitrogen), 1% GlutaMax, 1% HEPES buffer, and 1% 
penicillin/streptomycin plus 50 ng/mL mouse epidermal growth factor (EGF), 100 ng/mL 
Noggin, 1:100 N2 supplement, 1:50 B27 supplement, 500 ng/mL human recombinant R-
spondin1, and 1µM N-acetylcysteine) (7). Cultures were maintained for 6-8 days prior to viral 
transduction. 
 
Retroviral transduction 
Platinum E cells (Cell Biolabs) were used to generate viral supernatant as detailed elsewhere (1). 
Organoids were harvested and dissociated using a 20-gauge needle five times. The fragments 
were incubated for 5 min at 37°C in TripLE (Invitrogen). Advanced DMEM/F12 (Invitrogen) 
media containing 5% serum was added before the samples were centrifuged at 1,000g for 5 min. 
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After removing the supernatant, the cells were resuspended in a small volume of infection media 
(50% Wnt3a conditioned medium, 47% Advanced DMEM/F12, 1% GlutaMax, 1% HEPES 
buffer, and 1% penicillin/streptomycin plus 10µM Y27632 (sigma), 8 µg/mL polybrene (sigma), 
50 ng/mL EGF, 100 ng/mL Noggin, and 500 ng/mL R-spondin1). 250 µL of the cell suspension 
was combined with 250 µL of the retroviral supernatant and transferred to a 48-well culture 
plate. Each plate was centrifuged at 600g for 1 hr at 32°C, then incubated at 37°C for 6 hrs. After 
incubation, the samples were transferred to a 1.5 mL Eppendorf tube and spun down at 1,000g 
for 5 min. The pellet was resuspended in 100 µL of Matrigel and split into two wells of a 24-well 
culture plate. The cells were fed with 500 µL of crypt culture medium. After two days, the media 
was changed to crypt culture medium plus 2 µg/mL puromycin in order to select for organoids 
exhibiting incorporation of plasmid DNA. 
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CHAPTER III 
RESULTS 
 
Organoid growth 
Colonic crypts were harvested and plated in Matrigel. After 2-3 days, the crypts grew as 
spherical structures that began to bud into 3-dimensional organoids around day 5. 
 
Figure 2. Budding organoids six days after isolation. Scale bar, 100 µm. 
 
Figure 2 illustrates the growth of budding organoids six days following the initial isolation of 
crypts with the arrow indicating a bud. Organoids that were 6-8 days old displayed adequate 
growth and buds and were subsequently utilized for the viral transduction experiment. 
 
Viral transduction 
The organoids that were successfully transduced (approximately a 30% efficiency) expressed the 
dsRed gene under selection with puromycin. As shown in Figure 3, expression of the reporter 
gene (dsRed) increased as the organoids developed in culture. The non-transduced organoids did 
not express dsRed, but exhibited minimal autofluoresence over dead cells. Without the 
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expression of the puromycin resistant gene contained in the plasmid, the non-transduced 
organoids were not viable. This step was necessary to verify that the organoids were capable of 
being transduced through the use of the retroviral plasmid. 
 
 
 
Figure 3. Expression of dsRed in transduced organoids. Figure 3A. Transduced organoid 
expressing limited dsRed four days post transduction. Figure 3B. Increased expression of dsRed 
in a transduced organoid eleven days after the viral transduction. Figure 3C. Non-transduced 
organoids (negative control) showing only minimal autofluorescence over dead cells on day four. 
Figure 3D. Limited autofluorescence in a non-transduced organoid on day eleven. Scale bars, 50 
µm.  
Day 4 Day 11 
A 
D C 
B 
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CHAPTER IV 
CONCLUSIONS 
 
As colorectal cancer continues to affect the population, new models and methods to study this 
disease are emerging. The current method of using mouse models to study human cancers is 
inefficient and time consuming. Thus utilizing primary cell cultures to create an ex vivo model 
will improve the efficiency of cancer research.  
 
The stem cells isolated from the colon crypts developed into 3-dimensional organ like structures, 
called organoids. These organoids retained the architecture and integrity of the colon itself. 
Isolation of colonic crypts from a single mouse produced thousands of large intestinal organoids 
that were successfully passaged. Our findings indicate that wild-type organoids can be 
genetically manipulated by retroviral transduction. The viral transduction system can be 
modified with other genes in order to create an organoid model for various intestinal diseases, 
such as colitis. The organoid model is not limited to colonic tissue. Stem cells from other human 
tissues could produce an organoid model capable of studying other types of human cancers or 
diseases.  
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